Opioids for Breakthrough Cancer Pain. by Currow, DC & Clark, K
Reply to Mercadante et al on breakthrough cancer pain.  
Running title: Opioids for breakthrough cancer pain 
 
D C Currow1,2 
K Clark2,3 
 
1 IMPACCT, Faculty of Health, University of Technology Sydney, Ultimo, New South 
Wales. Australia.  
2 Australian national Palliative Care Clinical Studies Collaborative, University of Technology 
Sydney, Ultimo, New South Wales, Sydney. Australia. 
3 University of Sydney, Northern Clinical School, Royal North Shore Hospital, St Leonard’s. 
New South Wales. 
 
Corresponding author: 
Professor David C. Currow FAHMS 
IMPACCT, Faculty of Health 
University of Technology Sydney 
P O Box 123, Ultimo, New South Wales. Australia 2007  





Funding: This letter is not funded by any external funding sources.  
 
Conflict of Interest statement: All authors declare no conflict of interest. 
 





To the editor, The Oncologist 
Mercadante et al are to be commended for adding to the science of breakthrough cancer pain 
in this large, recently published cohort study. [1] The authors described differences in the 
characteristics of pain and subsequent analgesia with the use of breakthrough medications in 
3,892 people with cancer pain on regular low (<60mg oral morphine equivalent daily (OME)) 
and high (≥60mg OME) dose opioids.   
The characteristics of breakthrough cancer pain vary from person to person, and across 
populations. [2] The clinical response to breakthrough cancer pain (incident pain, 
spontaneous pain or both), once a regular dose of an opioid has been established, has been to 
prescribe a proportion of the regular dose of (mostly) the same opioid. Despite the ubiquitous 
nature of breakthrough cancer pain, the evidence remains poor for many key questions for its 
ideal management: [3]  
-  What should the proportion of the regular opioid dose be, accounting for any 
differences in formulation or route of administration?  
 
-  What should the lockout period / dose interval before an additional dose of 
breakthrough opioid can be given? and 
 
-  Should there be a limit on the number of doses that a patient can self-administer in 
any 24 hour period? 
 
A recent multi-site, randomised, double-blind study complements the findings of the study by 
Mercadante et al. [4] The study was undertaken to address a long-standing question in the 
evidence in the clinical literature about the ideal dose of opioid for breakthrough cancer pain. 
[3] In this study, three different dose proportions (1/6, 1/8, 1/12 of the fourth hourly dose) 
were studied for each person who was established on a regular dose of opioid (morphine or 
oxycodone) for cancer pain. The findings that the time to analgesia and harms were similar 
for all three proportions suggest that, from first principles, the lowest effective proportion 
(1/12) should be used, thus refining current recommendations. [5]  
Standardising dose proportions in future cohort studies will optimise the ability to compare 
across differing clinical practices, and further progress our understanding of this widespread 
cause of suffering. In the interim, using the lowest dose to achieve the desired clinical effect 
while minimising harms from opioids for pain should direct current practice, given that fewer 
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